Despite the development of cutting-edge genetic testing techniques and considerable progress in our understanding of the genetic basis of idiopathic pulmonary fibrosis (IPF), missing heritability and ...
Angiotensin-converting enzyme (ACE) inhibitors were found to be independently associated with reducing all-cause mortality in ...
AI models suggest IPF is a dysregulation of aging, not just accelerated aging, with unique gene expression patterns. Key pathways in IPF and aging include TGF-β signaling, oxidative stress, ...
Pooled patients treated with TTI-101 demonstrated a 9.4% decrease from baseline in fibrosis score at week 12, compared to a 2.4% decrease for the ...
ACE inhibitor use was associated with reduced all cause mortality in idiopathic pulmonary fibrosis in a matched real world ...
Among patients with idiopathic pulmonary fibrosis, the risk for all-cause mortality was significantly lower with vs. without angiotensin-converting enzyme inhibitor use started within 5 years before ...
-- BI 765423 has been developed to target IL-11, a key driver of fibrosis -- New study will investigate potential of BI 765423 to improve lung function for patients with idiopathic pulmonary fibrosis ...
Antifibrotic therapy shows similar efficacy in familial and sporadic IPF, with no significant differences in survival or acute exacerbations. Because familial idiopathic pulmonary fibrosis is ...
Quantitative CT metrics can be used to define progressive pulmonary fibrosis and have prognostic value in patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results